SINTX Technologies (SINT) investor relations material

Company overview and business model

• Develops, manufactures, and commercializes advanced silicon nitride ceramics for biomedical, antipathogenic, and industrial applications, with a focus on medical devices and high-performance industrial components.

• Biomedical products include FDA-cleared spinal and foot/ankle implants, with clinical use since 2008 and expansion into reconstructive surgery.

• Antipathogenic ceramics are used in products like masks and wound care to inactivate pathogens.

• Industrial ceramics serve electrical, aerospace, and other sectors requiring high strength and thermal stability.

• Manufacturing is based in Salt Lake City, Utah, with multiple quality certifications and primarily U.S. sales.

Financial performance and metrics

• As of August 11, 2026, 6,664,534 shares of common stock were outstanding; post-offering, up to 7,932,669 shares may be outstanding if all new warrants are exercised.

• Received a Nasdaq notice for non-compliance with minimum stockholders' equity, reporting $904,000 equity as of March 31, 2026, below the $2.5 million requirement.

• Submitted a compliance plan to Nasdaq on July 6, 2026; outcome pending.

Use of proceeds and capital allocation

• Will not receive proceeds from resale of shares by the selling stockholder.

• May receive up to $2.7 million in gross proceeds if all new warrants are exercised for cash; proceeds will be used for working capital and general corporate purposes.

• Management has broad discretion over use of proceeds, which may not improve financial condition or market value.